Review




Structured Review

Novartis midostaurin
Midostaurin, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/midostaurin/product/Novartis
Average 86 stars, based on 1 article reviews
midostaurin - by Bioz Stars, 2026-05
86/100 stars

Images



Similar Products

94
MedChemExpress pkc flt3 midostaurin
Pkc Flt3 Midostaurin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pkc flt3 midostaurin/product/MedChemExpress
Average 94 stars, based on 1 article reviews
pkc flt3 midostaurin - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

94
TargetMol midostaurin
Midostaurin, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/midostaurin/product/TargetMol
Average 94 stars, based on 1 article reviews
midostaurin - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

86
Novartis midostaurin
Midostaurin, supplied by Novartis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/midostaurin/product/Novartis
Average 86 stars, based on 1 article reviews
midostaurin - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

94
MedChemExpress pkc412
Pkc412, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pkc412/product/MedChemExpress
Average 94 stars, based on 1 article reviews
pkc412 - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier

86
Mastocytosis Society midostaurin rydapt 2017
Midostaurin Rydapt 2017, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/midostaurin rydapt 2017/product/Mastocytosis Society
Average 86 stars, based on 1 article reviews
midostaurin rydapt 2017 - by Bioz Stars, 2026-05
86/100 stars
  Buy from Supplier

93
Selleck Chemicals midostaurin
(A) Schematic overview of the organelle proteomics pipeline. FLT3 ITD-JMD (TKI-sensitive) and FLT3 ITD-TKD (TKI-resistant) Ba/F3 cells were left untreated or treated with 100 nM <t>midostaurin</t> for 24 h. Sequential extraction with six buffers generated six subcellular fractions, which were analyzed by MS-based proteomics in biological quadruplicates. Peptides were subjected to global proteomic profiling and phosphopeptide enrichment. (B) Intensity profiles of organelle-specific marker proteins across the six fractions. (C) Hierarchical clustering of protein profiles (scaled intensities) across fractions for untreated and midostaurin-treated FLT3-ITD cells. Statistically significant enriched gene ontology terms in each cluster are indicated.
Midostaurin, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/midostaurin/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
midostaurin - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

Image Search Results


(A) Schematic overview of the organelle proteomics pipeline. FLT3 ITD-JMD (TKI-sensitive) and FLT3 ITD-TKD (TKI-resistant) Ba/F3 cells were left untreated or treated with 100 nM midostaurin for 24 h. Sequential extraction with six buffers generated six subcellular fractions, which were analyzed by MS-based proteomics in biological quadruplicates. Peptides were subjected to global proteomic profiling and phosphopeptide enrichment. (B) Intensity profiles of organelle-specific marker proteins across the six fractions. (C) Hierarchical clustering of protein profiles (scaled intensities) across fractions for untreated and midostaurin-treated FLT3-ITD cells. Statistically significant enriched gene ontology terms in each cluster are indicated.

Journal: bioRxiv

Article Title: Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells

doi: 10.64898/2026.01.19.700272

Figure Lengend Snippet: (A) Schematic overview of the organelle proteomics pipeline. FLT3 ITD-JMD (TKI-sensitive) and FLT3 ITD-TKD (TKI-resistant) Ba/F3 cells were left untreated or treated with 100 nM midostaurin for 24 h. Sequential extraction with six buffers generated six subcellular fractions, which were analyzed by MS-based proteomics in biological quadruplicates. Peptides were subjected to global proteomic profiling and phosphopeptide enrichment. (B) Intensity profiles of organelle-specific marker proteins across the six fractions. (C) Hierarchical clustering of protein profiles (scaled intensities) across fractions for untreated and midostaurin-treated FLT3-ITD cells. Statistically significant enriched gene ontology terms in each cluster are indicated.

Article Snippet: Midostaurin (Selleck chemical, S8064) was used at 100 nM for 24 hours.

Techniques: Extraction, Generated, Phospho-proteomics, Marker

(A) Schematic representation of the bioinformatic strategy used to assign a cell compartment to proteins by using the SVM-algorithm. (B) Number of proteins assigned to cytosolic, nuclear, or organellar compartments in untreated and midostaurin treated FLT3-ITD cells. (C) Quantification of proteins changing their subcellular localization upon midostaurin treatment. (D) Sankey plot of protein translocation in midostaurin-treated FLT3 ITD-JMD . (E) Functional protein complexes redistributed between cytosol and nucleus in midostaurin-treated FLT3 ITD-JMD . (F) Sankey plot of protein translocation in midostaurin-treated FLT3 ITD-TKD cells. (G) Functional protein complexes redistributed between cytosol and nucleus in midostaurin-treated FLT3 ITD-TKD cells.

Journal: bioRxiv

Article Title: Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells

doi: 10.64898/2026.01.19.700272

Figure Lengend Snippet: (A) Schematic representation of the bioinformatic strategy used to assign a cell compartment to proteins by using the SVM-algorithm. (B) Number of proteins assigned to cytosolic, nuclear, or organellar compartments in untreated and midostaurin treated FLT3-ITD cells. (C) Quantification of proteins changing their subcellular localization upon midostaurin treatment. (D) Sankey plot of protein translocation in midostaurin-treated FLT3 ITD-JMD . (E) Functional protein complexes redistributed between cytosol and nucleus in midostaurin-treated FLT3 ITD-JMD . (F) Sankey plot of protein translocation in midostaurin-treated FLT3 ITD-TKD cells. (G) Functional protein complexes redistributed between cytosol and nucleus in midostaurin-treated FLT3 ITD-TKD cells.

Article Snippet: Midostaurin (Selleck chemical, S8064) was used at 100 nM for 24 hours.

Techniques: Translocation Assay, Functional Assay

Bar plots reporting the -log2 (p-value) of the GO-Term enrichment analysis of translocating proteins upon midostaurin treatment in sensitive and resistant FLT3-ITD cells. (C) Schematic representation of the spatial remodelling of key autophagic proteins upon midostaurin treatment in sensitive and resistant FLT3-ITD cells. (D) Heatmap reporting the intensity of the phosphorylation level of translocating autophagic proteins after midostaurin treatment in FLT3 ITD-JMD and FLT3 ITD-TKD . (E) Western blotting of LC3-II and p62 protein levels in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with midostaurin with or without bafilomycin A1 for 24 hours. (F) Bar plot reporting the percentage of viable cells measured by MTT assay. FLT3 ITD-JMD and FLT3 ITD-TKD were treated with 100nm of midostaurin treatment for 24h either alone or combined with 3 hours of starvation.

Journal: bioRxiv

Article Title: Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells

doi: 10.64898/2026.01.19.700272

Figure Lengend Snippet: Bar plots reporting the -log2 (p-value) of the GO-Term enrichment analysis of translocating proteins upon midostaurin treatment in sensitive and resistant FLT3-ITD cells. (C) Schematic representation of the spatial remodelling of key autophagic proteins upon midostaurin treatment in sensitive and resistant FLT3-ITD cells. (D) Heatmap reporting the intensity of the phosphorylation level of translocating autophagic proteins after midostaurin treatment in FLT3 ITD-JMD and FLT3 ITD-TKD . (E) Western blotting of LC3-II and p62 protein levels in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with midostaurin with or without bafilomycin A1 for 24 hours. (F) Bar plot reporting the percentage of viable cells measured by MTT assay. FLT3 ITD-JMD and FLT3 ITD-TKD were treated with 100nm of midostaurin treatment for 24h either alone or combined with 3 hours of starvation.

Article Snippet: Midostaurin (Selleck chemical, S8064) was used at 100 nM for 24 hours.

Techniques: Phospho-proteomics, Western Blot, MTT Assay

(A) Bar plot reporting the ECAR based measurements of glycolysis and glycolytic capacity in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with 100nm midostaurin for 24 hours and subjected to a glycolysis stress test. ( B ) OCR-derived assessments of basal respiration and ATP production in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with 100nm midostaurin for 24 hours and subjected to a mitochondrial stress test. (C) Representative electron microscopy images of steady-state FLT3 ITD-JMD and FLT3 ITD-TKD cells (m=mitochondria). (D) Bar plots reporting the number of cristae, the total cristae area and total mitochondria area in steady-state FLT3 ITD-JMD and FLT3 ITD-TKD cells. (E) Intensity profiles of the 168 proteins annotated in the MitoCarta database as mitochondrial proteins across the six fractions in each experimental condition. Colored boxes indicate the enriched GO-Term biological processes and cell compartments. (F) Heatmaps reporting the protein levels (scaled intensities) of the OXPHOS related proteins across the 6 fractions in each experimental condition.

Journal: bioRxiv

Article Title: Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells

doi: 10.64898/2026.01.19.700272

Figure Lengend Snippet: (A) Bar plot reporting the ECAR based measurements of glycolysis and glycolytic capacity in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with 100nm midostaurin for 24 hours and subjected to a glycolysis stress test. ( B ) OCR-derived assessments of basal respiration and ATP production in FLT3 ITD-JMD and FLT3 ITD-TKD . Cells were treated with 100nm midostaurin for 24 hours and subjected to a mitochondrial stress test. (C) Representative electron microscopy images of steady-state FLT3 ITD-JMD and FLT3 ITD-TKD cells (m=mitochondria). (D) Bar plots reporting the number of cristae, the total cristae area and total mitochondria area in steady-state FLT3 ITD-JMD and FLT3 ITD-TKD cells. (E) Intensity profiles of the 168 proteins annotated in the MitoCarta database as mitochondrial proteins across the six fractions in each experimental condition. Colored boxes indicate the enriched GO-Term biological processes and cell compartments. (F) Heatmaps reporting the protein levels (scaled intensities) of the OXPHOS related proteins across the 6 fractions in each experimental condition.

Article Snippet: Midostaurin (Selleck chemical, S8064) was used at 100 nM for 24 hours.

Techniques: Derivative Assay, Electron Microscopy

(A) Heatmap reporting the number of translocating proteins involved in carbohydrate, amino acids, peroxisome and lipid metabolism in FLT3 ITD-JMD and FLT3 ITD-TKD . (B) Bar plot reporting the ΔOCR of basal respiration after the inhibition of glucose usage (UK5099), glutamine usage (BPTES) and lipid usage (ETOMOXIR) for OXPHOS in FLT3 ITD-JMD and FLT3 ITD-TKD in absence and presence of 100nM midostaurin treatment for 24h. (C) Bar plot reporting the percentage of viable cells measured by MTT assay. FLT3 ITD-JMD and FLT3 ITD-TKD were treated with 100nm of midostaurin treatment for 24h either alone or combined with glucose, amino acid and lipid deprivation. (D) Representative immunofluorescence images of FLT3 localization before and after lipid deprivation in both permeabilized and non-permealized FLT3 ITD-JMD and FLT3 ITD-TKD . (E) Barplots showing the percentage of treatment-induced apoptosis (100 * (dead cells after treatment – death cells in control) / viable cells in control) in patient-derived blasts carrying FLT3-ITD in i) the JM domain, ii) both the JM and TK domain and iii) the TK domain upon the indicated treatments. Percentage of apoptotic cells was assessed by Annexin-V labeling.

Journal: bioRxiv

Article Title: Organelle proteomics reveals novel metabolic vulnerabilities in FLT3-ITD cells

doi: 10.64898/2026.01.19.700272

Figure Lengend Snippet: (A) Heatmap reporting the number of translocating proteins involved in carbohydrate, amino acids, peroxisome and lipid metabolism in FLT3 ITD-JMD and FLT3 ITD-TKD . (B) Bar plot reporting the ΔOCR of basal respiration after the inhibition of glucose usage (UK5099), glutamine usage (BPTES) and lipid usage (ETOMOXIR) for OXPHOS in FLT3 ITD-JMD and FLT3 ITD-TKD in absence and presence of 100nM midostaurin treatment for 24h. (C) Bar plot reporting the percentage of viable cells measured by MTT assay. FLT3 ITD-JMD and FLT3 ITD-TKD were treated with 100nm of midostaurin treatment for 24h either alone or combined with glucose, amino acid and lipid deprivation. (D) Representative immunofluorescence images of FLT3 localization before and after lipid deprivation in both permeabilized and non-permealized FLT3 ITD-JMD and FLT3 ITD-TKD . (E) Barplots showing the percentage of treatment-induced apoptosis (100 * (dead cells after treatment – death cells in control) / viable cells in control) in patient-derived blasts carrying FLT3-ITD in i) the JM domain, ii) both the JM and TK domain and iii) the TK domain upon the indicated treatments. Percentage of apoptotic cells was assessed by Annexin-V labeling.

Article Snippet: Midostaurin (Selleck chemical, S8064) was used at 100 nM for 24 hours.

Techniques: Inhibition, MTT Assay, Immunofluorescence, Control, Derivative Assay, Labeling